Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse

Health Affairs

Volumn 31, Issue 4, 2012, Pages 750-759

  Jacobs, Bruce L ^a   Zhang, Yun ^a   Skolarus, Ted A ^b   Hollenbeck, Brent K ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CAUCASIAN; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RECURRENT CANCER; SOCIAL STATUS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DIFFUSION OF INNOVATION; HEALTH CARE COSTS; HEALTH SERVICES MISUSE; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; RISK; SEER PROGRAM; UNITED STATES; UNNECESSARY PROCEDURES;

EID: 84862501158     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2011.1062     Document Type: Article

References (39)

1. Roehrig C, Miller G, Lake C, Bryant J. National health spending by medical condition, 1996-2005. Health Aff (Millwood). 2009;28(2):w358-67. DOI: 10.1377/hlthaff.28.2.w358.
2. Nguyen PL, Gu X, Lipsitz SR, Choueiri TK, Choi WW, Lei Y, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011;29(12):1517-24.
3. Ling CC, Burman C, Chui CS, Kutcher GJ, Leibel SA, LoSasso T, et al. Conformal radiation treatment of prostate cancer using inverselyplanned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys. 1996;35(4):721-30.
4. Vora SA, Wong WW, Schild SE, Ezzell GA, Halyard MY. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or highdose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68(4):1053-8.
5. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(4): 1124-9.
6. Jani AB, Su A, Milano MT. Intensitymodulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity. Urology. 2006;67(1):147-51.
7. Koper PC, Stroom JC, van Putten WL, Korevaar GA, Heijmen BJ, Wijnmaalen A, et al. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys. 1999;43(4): 727-34.
8. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr., Miller DW, Adams JA, et al. Comparison of conventionaldose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294(10):1233-9.
9. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8(6):475-87.
10. Staffurth J. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol). 2010;22(8):643-57.
11. Cannon DM, Lee NY. Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70(3):660-5.
12. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3DCRT and IMRT. Int J Radiat Oncol Biol Phys. 2003;56(1):83-8.
13. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al., editors. SEER cancer statistics review, 1975-2007. Bethesda (MD): National Cancer Institute; 2010.
14. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258-67.
15. To access the Appendix, click on the Appendix link in the box to the right of the article online
16. Diez Roux AV, Merkin SS, Arnett D, Chambless L, Massing M, Nieto FJ, et al. Neighborhood of residence and incidence of coronary heart disease. N Engl J Med. 2001;345(2):99-106.
17. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98(16):1134-41.
18. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-74.
19. Ries LAG, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, et al., editors. SEER cancer statistics review, 1975-2005. Bethesda (MD): National Cancer Institute; 2008.
20. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostatecancer survivors. N Engl J Med. 2008;358(12):1250-61.
21. Mell LK, Mehrotra AK, Mundt AJ. Intensity-modulated radiation therapy use in the U.S., 2004. Cancer. 2005;104(6):1296-303.
22. Spencer BA, Miller DC, Litwin MS, Ritchey JD, Stewart AK, Dunn RL, et al. Variations in quality of care for men with early-stage prostate cancer. J Clin Oncol. 2008;26(22): 3735-42.
23. Carreyrou J, Tamman M. A device to kill cancer, lift revenue. Wall Street Journal. 2010 Dec 7, Health Industry section.
24. Cahlon O, Hunt M, Zelefsky MJ. Intensity-modulated radiation therapy: supportive data for prostate cancer. Semin Radiat Oncol. 2008;18(1):48-57.
25. Konski A, Watkins-Bruner D, Feigenberg S, Hanlon A, Kulkarni S, Beck JR, et al. Using decision analysis to determine the costeffectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66(2):408-15.
26. Shen J, Andersen R, Brook R, Kominski G, Albert PS, Wenger N. The effects of payment method on clinical decision-making: physician responses to clinical scenarios. Med Care. 2004;42(3):297-302.
27. Centers for Medicare and Medicaid Services. Physician fee schedule search [Internet]. Baltimore (MD): CMS; [last modified 2012 Jan 8; cited 2012 Mar 6]. Available from: https://www.cms.gov/apps/physician-fee-schedule/search/search-results.aspx?Y=7&T=0&HT=0&CT=0&H1=77418&M=5
28. Mitchell JM, Sunshine JH. Consequences of physicians' ownership of health care facilities-joint ventures in radiation therapy. N Engl J Med. 1992;327(21):1497-501.
29. 42 US Code, sec. 1395nn.
30. Falit BP, Gross CP, Roberts KB. Integrated prostate cancer centers and over-utilization of IMRT: a close look at fee-for-service medicine in radiation oncology. Int J Radiat Oncol Biol Phys. 2010;76(5):1285-8.
31. 42 US Code, sec. 1395nn(b)(2).
32. Urorad Healthcare. FAQ's [Internet]. Humble (TX): Urorad Healthcare; [cited 2012 Jan 27]. Available from: http://online.wsj.com/public/resources/documents/uroradwhois12082010.pdf
33. Pollack A. Hospitals look to nuclear tool to fight cancer. New York Times. 2007 Dec 26, Business section.
34. Mitchell JM, Lagalia RR. Controlling the escalating use of advanced imaging: the role of radiology benefit management programs. Med Care Res Rev. 2009;66(3):339-51.
35. Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010;363(19): 1822-32.
36. Wu AW, Snyder C, Clancy CM, Steinwachs DM. Adding the patient perspective to comparative effectiveness research. Health Aff (Millwood). 2010;29(10):1863-71.
37. Miller FG, Pearson SD. Coverage with evidence development: ethical issues and policy implications. Med Care. 2008;46(7):746-51.
38. Keenan PS, Neumann PJ, Phillips KA. Biotechnology and Medicare's new technology policy: lessons from three case studies. Health Aff (Millwood). 2006;25(5):1260-9.
39. Carino T, Williams RD 2nd, Colbert AM, Bridger P. Medicare's coverage of colorectal cancer drugs: a case study in evidence development and policy. Health Aff (Millwood). 2006;25(5):1231-9.